In a 42-year-old male with hypertension treated with olmesartan who has three days of loss of taste, a dry cough, periumbilical pain, occasional constipation, low‑grade fever, clear lungs, normal heart rate, oxygen saturation, and blood pressure, what is the most likely diagnosis and recommended outpatient treatment?

Diagnosis and Treatment

This patient most likely has COVID-19 or another viral respiratory infection, and the periumbilical pain is concerning for olmesartan-induced enteropathy given his chronic use of this medication.

Clinical Reasoning

Primary Diagnosis: Viral Respiratory Infection (likely COVID-19)

The constellation of loss of taste (ageusia), dry cough, and low-grade fever (99.8°F) in a 42-year-old is highly suggestive of a viral upper respiratory infection, with COVID-19 being a leading consideration given the characteristic loss of taste. The clear lung examination with normal oxygen saturation (99%) indicates no pneumonia at this time.

Secondary Concern: Olmesartan-Induced Enteropathy

The periumbilical pain and occasional constipation in a patient taking olmesartan 40 mg warrant serious consideration of olmesartan-associated enteropathy (OAE). While this condition classically presents with chronic diarrhea and weight loss 12, gastrointestinal symptoms can be variable and include:

• Abdominal pain and discomfort 23
• Nausea 2
• Constipation or diarrhea
• Symptoms can develop months to years after drug initiation 34

The FDA label explicitly warns about sprue-like enteropathy with olmesartan 1, and recent evidence shows strong associations between olmesartan and both enteropathy (ROR 8499.53) and colitis (ROR 2.56) 2.

Immediate Treatment Plan

For Viral Respiratory Infection:

• Supportive care: Rest, hydration, acetaminophen for fever (avoid NSAIDs as they can interfere with BP control 5)
• Monitor for worsening: Return precautions for dyspnea, chest pain, persistent high fever
• Consider COVID-19 testing if available
• Self-isolation until symptoms resolve

For Gastrointestinal Symptoms and Olmesartan Concern:

Switch olmesartan to an alternative antihypertensive immediately. Given his well-controlled BP (130/80 mmHg) on olmesartan 40 mg, reasonable alternatives include:

1. ACE inhibitor: Lisinopril 10-20 mg daily (as successfully used in a similar case 6)
2. Alternative ARB: Losartan 50-100 mg daily (if ACE inhibitor not tolerated, though cross-reactivity possible)
3. Calcium channel blocker: Amlodipine 5-10 mg daily

The 2025 AHA/ACC guidelines recommend ACEi or ARB plus CCB and diuretic for optimal BP control 57, so switching to an ACE inhibitor or adding a CCB would align with guideline-directed therapy.

Critical Follow-up Actions

Within 48-72 Hours:

• Reassess gastrointestinal symptoms after olmesartan discontinuation
• If abdominal pain worsens or diarrhea develops: Urgent gastroenterology referral for EGD with duodenal biopsies 3
• Monitor BP to ensure continued control on new medication

Red Flags Requiring Immediate Evaluation:

• Severe or worsening abdominal pain
• Bloody diarrhea
• Significant weight loss
• Persistent vomiting
• Respiratory distress or hypoxemia

Important Caveats

Olmesartan-induced enteropathy can be severe and debilitating 23, with patients experiencing:

• Profound weight loss (up to 40 pounds) 3
• Villous atrophy mimicking celiac disease 34
• Symptoms persisting for months if drug not discontinued 8

Complete resolution typically occurs after olmesartan discontinuation 634, though some severe cases may benefit from a steroid taper 3. The diagnosis is often delayed due to nonspecific symptoms and normal-appearing endoscopy 3, making clinical suspicion essential.

Do not rechallenge with olmesartan - reintroduction causes immediate symptom recurrence 8.